MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$68K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Accounts payable
Proceeds from convertible debt ...
Consumer Health Products
Others
Negative Cash Flow Breakdown
Regenerative Biotech
Consumer Health Products
Insurance premium financing paya...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Regenerative Biotech
0
0
0
-
Consumer Health Products
414
226
704
-
Product revenue
414
226
704
-
Regenerative Biotech
0
0
0
-
Consumer Health Products
391
206
646
-
Cost of sales
391
206
646
-
Regenerative Biotech
948
563
2,653
-
Consumer Health Products
0
0
0
-
Research and development
948
563
2,653
-
Sales and marketing
16
18
67
-
General and administrative
751
1,045
4,253
-
Total operating expenses
2,106
1,832
7,619
-
Other segment items
3
-5
-46
-
Net loss
-1,695
-1,601
-1,687
-1,700
Share-based compensation expense
223
632
493
495
Depreciation
1
1
1
1
Amortization of operating lease right-of-use assets
27
27
26
24
Accounts receivable
-7
0
13
-2
Inventory
-15
-1
-6
-5
Prepaid research and development
65
-
-35
0
Prepaid expenses and other current assets
-59
-22
-32
-16
Deferred financing costs
-
-
0
0
Long-term prepaid contracts
-1
105
-44
-76
Accounts payable
518
-215
141
-39
Operating lease liability
-28
-26
-25
-25
Accrued and other current liabilities
174
307
205
-236
Deferred revenue
263
88
124
-21
Insurance premium financing payable
-69
-68
-46
-63
Net cash used in operating activities
-569
-937
-664
-1,465
Proceeds from convertible debt related party
-
-
0
0
Proceeds from issuance of common stock
-
-
700
2,000
Proceeds from exercise of warrants
-
-
0
0
Payments on convertible debt related party
-
-
0
0
Proceeds from convertible debt related party
500
-
-
-
Net cash provided by financing activities
500
-
700
2,000
Effect of exchange rate changes on cash
1
4
-3
-2
Net decrease in cash and cash equivalents
-68
-933
33
533
Cash and cash equivalents at the beginning of the year
419
1,352
1,319
2,486
Cash and cash equivalents at the end of the period
351
419
1,352
1,319
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from
convertible debt related...
$500K
Net cash provided by
financing activities
$500K
Effect of exchange rate
changes on cash
$1K
(200.00%↑ Y/Y)
Net decrease in cash
and cash...
-$68K
(96.00%↑ Y/Y)
Canceled cashflow
$501K
Accounts payable
$518K
(618.00%↑ Y/Y)
Deferred revenue
$263K
(76.51%↑ Y/Y)
Share-based compensation
expense
$223K
(-78.18%↓ Y/Y)
Accrued and other
current liabilities
$174K
(-49.12%↓ Y/Y)
Prepaid expenses and
other current assets
-$59K
(41.58%↑ Y/Y)
Amortization of operating
lease right-of-use...
$27K
(-43.75%↓ Y/Y)
Inventory
-$15K
(71.70%↑ Y/Y)
Accounts receivable
-$7K
(96.90%↑ Y/Y)
Long-term prepaid
contracts
-$1K
(99.27%↑ Y/Y)
Depreciation
$1K
(-66.67%↓ Y/Y)
Consumer Health Products
$414K
Net cash used in
operating activities
-$569K
(66.51%↑ Y/Y)
Canceled cashflow
$1,288K
Product revenue
$414K
Net loss
-$1,695K
(51.32%↑ Y/Y)
Canceled cashflow
$414K
Insurance premium
financing payable
-$69K
(63.68%↑ Y/Y)
Prepaid research and
development
$65K
(275.68%↑ Y/Y)
Operating lease liability
-$28K
(37.78%↑ Y/Y)
Total operating
expenses
$2,106K
Other segment items
$3K
Research and development
$948K
General and
administrative
$751K
Cost of sales
$391K
Sales and marketing
$16K
Regenerative Biotech
$948K
Consumer Health Products
$391K
Buy us a coffee
Harvard Apparatus Regenerative Technology, Inc. (HRGN)
Harvard Apparatus Regenerative Technology, Inc. (HRGN)